We now find that MYCN‐A high‐risk neuroblastoma tumor growth is also reduced in p50(f/f);Lys‐Cre mice, further validating the idea of targeting myeloid p50 as a therapeutic strategy for cancer therapy. This evidence concerns the gene MYCN and neuroblastoma.